Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Shore

Showing results (391-400 of 590) with videos related to

Pageof 59
Sort By:
Future Oncology (London, England)|October 26, 2023
TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancerNeeraj Agarwal, Fred Saad, Arun A Azad, et al.
Therapeutic Advances in Urology|February 14, 2018
Pharmacokinetic and pharmacodynamic comparison of subcutaneous <i>versus</i> intramuscular leuprolide acetate formulations in male subjectsDaniel Saltzstein, Neal D Shore, Judd W Moul, et al.
JCO Precision Oncology|September 15, 2022
Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor CancerEdward D Esplin, Sarah M Nielsen, Sara L Bristow, et al.
Future Oncology (London, England)|April 1, 2025
Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patientsRana R McKay, Ashley E Ross, Mark A Preston, et al.
Cancer|April 11, 2016
Risk of brain metastases in patients with nonmetastatic lung cancer: Analysis of the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) dataPriscila H Goncalves, Stephanie L Peterson, Fawn D Vigneau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2018
Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate CancerShilpa Gupta, Luke T Nordquist, Mark T Fleming, et al.
Cancers|October 14, 2023
Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate CancerFred Saad, Daniel J George, Michael S Cookson, et al.
Urology Practice|August 18, 2023
The Need for Survivorship Care in Genitourinary Cancers: Considerations from SUO and LUGPAHamed Ahmadi, Michael A S Jewett, Neal D Shore, et al.
BJU International|September 10, 2022
Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trialNeal D Shore, Arnulf Stenzl, Christopher Pieczonka, et al.
Obesity Surgery|June 1, 2011
The long-term risk of venous thromboembolism following bariatric surgeryKimberley Eden Steele, Michael A Schweitzer, Gregory Prokopowicz, et al.
Pageof 59

Showing results (391-400 of 590) with videos related to

Sort By:
Pageof 59
Future Oncology (London, England)|October 26, 2023
TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancerNeeraj Agarwal, Fred Saad, Arun A Azad, et al.
Therapeutic Advances in Urology|February 14, 2018
Pharmacokinetic and pharmacodynamic comparison of subcutaneous <i>versus</i> intramuscular leuprolide acetate formulations in male subjectsDaniel Saltzstein, Neal D Shore, Judd W Moul, et al.
JCO Precision Oncology|September 15, 2022
Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor CancerEdward D Esplin, Sarah M Nielsen, Sara L Bristow, et al.
Future Oncology (London, England)|April 1, 2025
Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patientsRana R McKay, Ashley E Ross, Mark A Preston, et al.
Cancer|April 11, 2016
Risk of brain metastases in patients with nonmetastatic lung cancer: Analysis of the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) dataPriscila H Goncalves, Stephanie L Peterson, Fawn D Vigneau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2018
Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate CancerShilpa Gupta, Luke T Nordquist, Mark T Fleming, et al.
Cancers|October 14, 2023
Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate CancerFred Saad, Daniel J George, Michael S Cookson, et al.
Urology Practice|August 18, 2023
The Need for Survivorship Care in Genitourinary Cancers: Considerations from SUO and LUGPAHamed Ahmadi, Michael A S Jewett, Neal D Shore, et al.
BJU International|September 10, 2022
Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trialNeal D Shore, Arnulf Stenzl, Christopher Pieczonka, et al.
Obesity Surgery|June 1, 2011
The long-term risk of venous thromboembolism following bariatric surgeryKimberley Eden Steele, Michael A Schweitzer, Gregory Prokopowicz, et al.
Pageof 59